

PERSONAL INFORMATION



Evelina Tacconelli

✉ evelina.tacconelli@univr.it

PUBBLICAZIONI

Numero totale di pubblicazioni in riviste peer-reviewed: 458
 Numero totale di citazioni: 52.008 (Google Scholar)
 Indice H: 89 (Google Scholar)

CAMPI DI INTERESSE

Medicina personalizzata nelle malattie infettive, gestione corretta degli antimicrobici (antimicrobial stewardship), resistenza antimicrobica (impatto clinico e terapia), prevenzione delle infezioni associate all'assistenza, COVID-19, preparazione alle pandemie (pandemic preparedness), medicina basata sull'evidenza.

ATTIVITÀ Professionali

Dal 5/2023	Chief Scientific Officer di ECRAID (European Clinical Research Alliance on Infectious Diseases), Utrecht, Netherlands
Dal 10/ 2018	Direttore della UOC di Malattie Infettive, ID-CARE (Infectious Diseases Centre for TrAnslational REsearch), Università di Verona (UNIVR)
Dal 10/ 2017	Professore ordinario, Malattie Infettive, UNIVR
Dal 01/ 2021	Lecturer on Antimicrobial Resistance, Dept. Internal Medicine I, Tübingen University, Germany
2013 - 2020	Direttore della Divisione di Malattie Infettive, Dipartimento Medicina Interna I, University Hospital Tübingen University, Germania
2012 – 2020	Direttore della DZIF (German Center for Infection Research - Centro tedesco per la ricerca sulle infezioni) Research Clinical Unit on healthcare associated infections and antimicrobial resistance, Tübingen University, Germania
2012 – 2017	Professore ordinario, Malattie Infettive, University of Tübingen, Germania
2013 - 2018	Direttore Medico del Comprehensive Center for infectious Diseases, University Hospital Tübingen, Germania
2003 - 2007	Lecturer on Medicine, Infectious Diseases, Beth Israel Deaconess medical Centre and Harvard Medical School, Boston, USA
1999 - 2013	Ricercatore di Malattie Infettive, Università Cattolica Sacro Cuore, Roma
1997 - 1999	Specializzazione in Malattie Infettive, Università Cattolica Sacro Cuore, Roma

EDUCAZIONE

09/1986 - 07/1992	Laurea in Medicina e Chirurgia (09/1986 – 07/1992; 110/110 cum laude), Università Cattolica di Roma
09/1992 - 07/1996	Specializzazione in Malattie Infettive, Università Cattolica Sacro Cuore, Roma (60/60 cum laude)
09/1997- 06/1998	Master per Operatori di Sanità Pubblica, Università la Sapienza, Roma

Riconoscimenti

- | | |
|------|---|
| 2024 | European Society of Clinical Microbiology and Infectious Diseases "Excellence Lifetime Achievement Award" |
| 2023 | "Forbes Fellow", Australasian Society for Infectious Diseases |
| 2020 | "Lowbury Lecture 2020 for Excellence in Research in Prevention of Healthcare Associated Infections", Hospital Infections Society, UK |
| 2020 | Profile eminent ID specialists: Lancet Infectious Disease Oct 2020 |
| 2004 | "Young Investigator Award for Clinical Microbiology and Infectious Diseases" European Society of Clinical Microbiology and Infectious Diseases |
| 2003 | "Young Investigator Award for the Study on Antibiotic Resistance", Slovak Society of Chemotherapy, Slovakia |
| 1998 | "Junior Scholarship Award, University of London, for Curricula Studiorum and Abstract Presentation at 4 th International Congress on Drug Therapy in HIV Infection", Glasgow |
| 1997 | National scholarship for studies on AIDS, National Institute of Health, Italy |

EDITORIAL BOARDS (selezione)

- | | |
|-------------|---|
| Dal 2025 | Editorial Board, JAMA Network Open |
| Dal 2020 | Senior Editor, Journal of Antimicrobial Chemotherapy |
| Dal 2014 | Scientific Committee, Clinical Microbiology and Infection |
| Dal 2012 | International Advisory Board, Lancet Infectious Diseases |
| 2009 - 2019 | Editorial Board, Journal of Antimicrobial Chemotherapy |
| 2004 - 2013 | Associated Editor, Clinical Microbiology and Infection |

SOCIETA' SCIENTIFICHE e BOARD (selezione)

- | | |
|-----------|--|
| 2026 | WHO Clinical Guidance aimed at supporting optimal antibiotic development in adults and neonates, expert board |
| 2026 | WHO Expert Group on Antimicrobial resistance (AMR) Accountability Index, panel member |
| 2026 | One World Health Summit 2026, Lyon, France, expert board |
| 2025 | WHO Target Product Profile, expert member |
| 2025 | Dutch Organisation for knowledge and innovation in health, healthcare and well-being (ZonMw), grant panel |
| 2023 | WHO Research & Development of Antibacterial Treatments, expert member |
| Dal 2022 | Cohort Coordination Board (in collaboration with the European Commission), chair |
| 2022 | AMR stockpiling study group (public health with the European Commission), expert member |
| 2021-2024 | Gruppo Nazionale AIFA per la terapia antibiotica, coordinatore |
| Dal 2021 | Gruppo di coordinamento regionale PanFlu, membro del panel |
| Dal 2021 | Gruppo di lavoro per la coordinazione del Piano Nazionale per il Controllo della Resistenza agli Antimicrobici, Ministero della Sanità, membro del panel |
| 2021-2024 | ESCMID guidelines for the prevention of surgical site infections, chair |
| 2021-2022 | ESCMID guidelines for screening policies for healthcare workers to reduce the spread of SARS-CoV-2, chair |
| 2021-2023 | Gruppo di Lavoro per le terapie anti SARS-CoV-2 con anticorpi monoclonali della Regione Veneto, membro del panel |
| 2021 | Gruppo di Lavoro per le terapie anti SARS-CoV-2 con anticorpi monoclonali, Ministero della Sanità, membro del panel |
| 2020-2024 | Comitato Tecnico Scientifico per il controllo di SARS-CoV-2 della Regione Veneto, membro del panel |

Dal 2024	EUCIC Working Group on Guidelines, chair
2020	Gruppo di Lavoro per l'appropriatezza dei ricoveri ospedalieri dei pazienti con SARS-CoV-2, AGENAS, membro del panel
2020-2021	WHO Expert Group on Identifying Priority Fungal Pathogens, expert member
Dal 2019	Gruppo Multidisciplinare per l'implementazione della stewardship antibiotica, PNCAR, della Regione Veneto, coordinatore
2019-2024	WHO Essential Medicine List, Antibiotics Working Group, expert member
2019	Selection Committee for the Department of Health and Social Care Antimicrobial Resistance Research Capital Funding Competition, NHS, United Kingdom (Capital: £32 million), coordinator deputy
Dal 2019	Master/ infermiere specialista nella sorveglianza epidemiologica e controllo delle infezioni correlate all'assistenza sanitaria (ICAS), Università di Verona, coordinatore
2018-2022	Scientific Board of JPI-AMR (Joint Programming Initiative on Antimicrobial Resistance, European Commission), expert member
Dal 2018	Comitato Terapeutico Regione Veneto, membro del panel
Dal 2018	Comitato Scientifico IRCCS Sacro Cuore – Don Calabria', Negrar, membro del panel
2015-2024	European Committee of Infection Control – EUCIC, chair
Dal 2022	ESCMID guidelines to control of hospital spreading of multidrug-resistant gram-negative bacteria, chair (first document and 2025 update)
2009-2018	European Center for Diseases Control (ECDC) Consultant for antibiotic stewardship and AMR
2018 - 2024	WHO Priority List of antimicrobial resistant bacteria for R&D of effective antibiotics, chair of technical group (first document and 2024 update)
2017 - 2019	ESCMID Guidelines Officer of Infectious Diseases and Clinical Microbiology
2016 - 2019	ESCMID guidelines for decolonisation of MDR gram-negative bacteria, chair
2009 - 2017	ESCMID Education Officer of Infectious Diseases and Clinical Microbiology
2014 - 2017	Clinical Advisory Board, HZI (Helmholtz Zentrum für Infektionsforschung, Germany), expert member
2014 - 2016	Advisory Board, German Society for Infectious Diseases, DGI (Deutsche Gesellschaft für Infektiologie, Germany), expert member
2009 - 2013	Gruppo di Studio per il controllo della Resistenza agli Antibiotici nei pazienti ospedalizzati SIMIT, coordinatore
2012 - 2013	External Affairs Committee, SHEA (Society of Healthcare Epidemiologists of America), expert member
2012 - 2013	ESCMID Study Group on Infections in the Elderly (ESGIE), chair
2008 - 2012	ISC (International Society of Chemotherapy) Working Group on MRSA - Risk assessment, chair

Date	Progetti nazionali e internazionali	Sponsor	Ruolo – budget Università / budget totale, €
2025 - 2027	BE-Ready NOW	HorizonEurope	Partner €800.000/ €100.000.000
2025 - 2028	FAIR: Public health value, cost-effectiveness Analysis and modelling of Reserve antibiotics	GARDP	Coordinatore €785.900
2024 - 2028	PIPELINE: Pregnancy and Infant Preparedness Platform IN Europe	HorizonEurope	Partner €110.000/ €9.999.973
2024 - 2029	EU-PROACT: A European Proactive Adaptive Clinical Trials Network	HorizonEurope	Partner €202.406/ €17.042.172

2023 - 2026	COMECT: COOrdination MEchanism for Cohorts and Trials	HorizonEurope	Partner €451.875/ €3.055.297
2022 - 2023	CLEARER: Current cLinical scEnARios for the use of cefidErocol in multidrug-Resistant infections	GARDP	Coordinatore €65.000
2022 - 2023	Update the 2017 WHO BPPL for research and development of new antibacterial treatments.	WHO	Coordinatore €118.000
2021 - 2025	VERDI: SARS-CoV2 variants evaluation in pregnancy and paediatrics cohorts.	HorizonEurope	Partner € 355.000/€15.395.599
2021 - 2023	Adaptive group sequential randomized control trial (Phase III) to assess the efficacy of mAb	AIFA	Coordinatore € 839.095
2021 - 2026	PRIMAVERA: Vaccines And Monoclonal antibodies: Predicting the Impact on AMR and an Economic evaluation.	IMI	Partner € 280.275 / € 9.250.000
2021 - 2024	VACCELERATE-Italy: European Corona Vaccine Trial Accelerator Platform.	Horizon2020	Coordinatore nazionale € 92.361 / € 29.967.975
2021 - 2026	ECRAID BASE: European Clinical Research Alliance on Infectious Diseases	Horizon2020	Partner € 999.815/ € 29.969.875
2021 - 2026	REVERSE: Prevention and management tools for reducing antibiotic Resistance in high prevalence	Horizon2020	Coordinatore nazionale € 2.017.882 / € 13.953.194
2020 - 2024	ORCHESTRA: Connecting European Cohorts to Increase Common and Effective Response to SARS.	Horizon2020	Coordinatore € 2.204.998 / € 27.887.540
2020 - 2022	WHO Solidarity Trial: international clinical trial to help find an effective treatment for COVID-19.	WHO	Coordinatore nazionale In-kind contribution
2020 - 2022	ENACT: Alliance against COVID-19.	Fondazione CariVerona	WP leader € 886.234
2020 - 2025	EU-RESPONSE: European Research and Preparedness Network for Pandemics and Emerging Infectious Diseases.	Horizon2020	Coordinatore nazionale € 217.047 / €15.719.450
2020 - 2021	SARS-CoV-2 Surveillance in school and public places.	CORIS Regione Veneto	Partner € 338.000
2019 - 2021	Development of a web tool to perform surveillance connected to antibiotic prescription in hospital and community.	CORIS Regione Veneto	Coordinatore € 210.000
2019 - 2024	VALUE DX : The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use.	IMI	WP leader € 83.705 / € 6.799.100
2019 - 2023	Factors And Barriers for Preparation of a Phase 3 RCS with ExPEC10V in Adults Aged 60-85 Years With UTI.	IMI	Partner € 1.109.716 / € 83.033.010
2019	Systematic review to develop a WHO Index integrated in the AWARE index to measure optimal antibiotic usage	WHO	Coordinatore € 21.000
2019	WHO Tender: Duration of antibiotic therapy to treat community acquired pneumonia.	WHO	Coordinatore € 22.000
2019	DZIF-PREDICT Validation of the BLOOMY score for mortality.	DZIF	Coordinatore € 89.900
2019-2022	COMBACTE-MAGNET Understanding of the epidemiology and clinical impact of CDI	IMI	Partner € 2.294.881 / € 75.340.000
2020- 2023	SENTINELLA: Rapid identification of SARS-CoV-2 in vulnerable population	Fondazione Veronese	Coordinatore € 737.640
Dal 2019	BIOSTEPS: Personalised surgical prophylaxis in pancreatic surgery in high AMR prevalence	AIFA	Partner € 100.000
2018-2021	Understanding and modelling reservoirs, vehicles and transmission of ESBL-Ent. in the community and LTCF.	Horizon 2020	WP leader € 680.000
2018-2020	Combination therapy to treat sepsis due to carbapenem-Resistant bacteria in adult and paediatric population	GARDP	Coordinatore € 120.000
2015-2020	DZIF-R-Net Surveillance for antibiotic resistant infections	DZIF	Partner

			€ 95.900
2012-2020	DZIF (German Center for Infectious Diseases Research) CT for research on prevention and treatment of HAIs	DZIF	Coordinatore € 1.101.000
2018-2019	Increasing communication, awareness and data sharing in a global approach against resistance	JPI-AMR	Partner In-kind contribution
2018-2019	Global Antimicrobial resistance Platform for ONE Burden Estimates.	JPI-AMR	Partner In-kind contribution
2018-2019	Bridging the gap between human and animal surveillance data, antibiotic policy, and stewardship.	JPI-AMR	Coordinatore € 50.000
2016-2019	Surveillance of multidrug resistant bacteria in human and animal in Baden Württemberg	Baden-Württemb.	Coordinatore € 340.000
2015-2019	DZIF-ABSOLUTE Antimicrobial stewardship to reduce resistance	DZIF	Partner € 99.700
2015-2019	DZIF-BLOOMY Solution for the improvement of bloodstream infections	DZIF	Coordinatore € 72.600
2017-2018	Burden of antibiotic resistant infection (GLASS initiative)	WHO	Coordinatore € 35.000
2016-2018	COMBACTE-MAGNET- ICU-ASPIRE	IMI	Partner € 89.000
2014-2018	DRIVE-AB Driving reinvestment in R&D and appropriate usage of antibiotics	IMI	Partner € 373.600
2016-2017	Priority list for AMR pathogens for the R&D for new antibiotics.	WHO	Coordinatore € 144.000
2012-2015	DZIF-ATHOS Antimicrobial stewardship in community and healthcare facilities.	DZIF	Partner € 63.000
2012-2015	DZIF- SPECTRUM- Risk factors for Clostridium difficile at hospital admission"	DZIF	Partner € 60.000
2012-2015	"Excellence in Research in Infectious Diseases", University of Tübingen.	EKUT	Coordinatore € 240.000
2010-2014	SATURN: impact of specific antibiotic therapies on the prevalence of human host resistant bacteria.	FP7	WP leader € 848.000
2011-2013	Preserving old antibiotics for the future: assessment of clinical efficacy by a PKP	FP7	Partner € 264.640
2010-2013	European Grant DG Sanco Implementing Strategic Bundles for Infection Prevention & Management	DG Sanco	Partner € 87.156

10 pubblicazioni (selezione)

1. Garlasco J, ... **Tacconelli E**. The Emerging Resistance Index: tracking early resistance to new antibiotics. **Lancet Infect Dis.** 2026 May;26(5):e219-e227 (Impact Factor 31)
2. Gusinow R, ... **Tacconelli E and Hasenauer J**; ORCHESTRA study group. Latent transition analysis for longitudinal studies of post-acute infection syndromes. **Nature Communications** 2026 Feb 10;17(1):2557 (Impact Factor: 17)
3. Sati H, ... **Tacconelli E**. The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance. **Lancet Infect Dis.** 2025 Sep;25(9):1033-1043 (Impact Factor 31)
4. Carrara E, .. **Tacconelli E**. How to tailor recommendations on the treatment of multi-drug resistant Gram-negative infections at country level integrating antibiotic stewardship principles within the GRADE-ADOLOPMENT framework. **Lancet Infect Dis** 2024 Feb;24(2):e113-e126 (Impact Factor 31)
5. **Tacconelli E**, et al. Development and validation of BLOOMY prediction scores for 14-day and 6-month mortality in hospitalized adults with bloodstream infections: a multicenter, prospective, cohort study. **Lancet Infect Dis** 2021, Dec 1-12 (Impact Factor 31)
6. Carrara E, .. **Tacconelli E**. ESCMID guidelines on testing for SARS-CoV-2 in asymptomatic individuals to prevent transmission in the health care setting. **Clin Microbiol Infect.** 2022 Feb (Impact Factor 8,5)

7. **Tacconelli E**, et al. Surveillance for control of antimicrobial resistance. **Lancet Infect Dis** 2017, Oct, 1-8 (Impact Factor 31; citations 457)
8. **Tacconelli E**, et al. Discovery, research and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria. **Lancet Infect Dis** 2018 Mar;18(3):318-327 (Impact Factor 31; **7560 citations**)
9. Savoldi A, ... **Tacconelli E**. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-Analysis in World Health Organization Regions **Gastroenterology** 2018 (Impact Factor 25; 1481 citations)
10. Baur D,... **Tacconelli E**. Effect of antibiotic stewardship on the incidence of infection and colonization with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. **Lancet Infect Dis** 2017 Sep;17(9):990-1001 (Impact Factor 31; citations 1027)

Autorizzo il trattamento dei miei dati personali ai sensi del D.Lgs. n. 101 del 10/08/2018, "Adeguamento al Regolamento UE 2016/679" e successive modifiche e integrazioni, limitatamente agli scopi per i quali questo CV è stato inviato.

Dichiaro l'assenza di conflitto di interessi in ambito sanitario negli ultimi due anni dalla data di sottoscrizione.

Dichiaro la veridicità dei dati ai sensi degli artt. 19, 46, 47 e 76 del D.P.R. 28 dicembre 2000, n. 445 e la consapevolezza delle sanzioni penali, nel caso di dichiarazioni non veritiere, di formazione o uso di atti falsi.

Verona, 24/04/2026

Evelina Tacconelli